Zepbound vs compounded tirzepatide compared: FDA approval, dosing, cost, and safety, plus why compounded versions are now largely unavailable.
Zepbound is an FDA-approved, brand-name tirzepatide injection made by Eli Lilly, while compounded tirzepatide was a pharmacy-mixed version of the same active ingredient sold during a national drug shortage. The two share a molecule but not a regulatory path, a quality standard, or a price tag. Large-scale compounding of tirzepatide has largely ended in the United States.
What Zepbound Actually Is
Zepbound (tirzepatide) is a once-weekly injection approved by the FDA for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. It is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. In the SURMOUNT trials, participants on the highest doses lost about 20% of their body weight on average over roughly 72 weeks, combined with diet and exercise.
Approved doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per week. Zepbound is sold as single-dose pens and, through the manufacturer's direct pharmacy, as single-dose vials.
What Compounded Tirzepatide Was
Compounded tirzepatide was prepared by state-licensed compounding pharmacies, typically from bulk tirzepatide and often blended with vitamin B12, vitamin B6, or glycine. It was dispensed in vials with insulin syringes rather than in pre-filled pens.
Compounding is legal when an FDA-approved drug is unavailable, or when a patient has a documented clinical need a commercial product cannot meet. During the tirzepatide shortage, that rule let pharmacies produce a substitute.
The FDA declared the tirzepatide shortage resolved in late 2024 and gave compounding pharmacies a limited wind-down window that closed in early 2025. Compounded tirzepatide is not FDA-approved, and it is no longer widely available in the United States.
Zepbound vs Compounded Tirzepatide at a Glance
| Feature | Zepbound | Compounded tirzepatide |
|---|---|---|
| FDA approval | Approved for weight management and sleep apnea | Not FDA-approved |
| Active ingredient | Tirzepatide | Tirzepatide, sometimes with added vitamins |
| Dosing | Fixed single-dose pen or vial, 2.5 to 15 mg weekly | Varies by pharmacy, measured by syringe |
| Quality oversight | Manufacturing inspected by the FDA | State board oversight, limited federal review |
| Typical monthly cost | Over $1,000 list price before insurance or savings | Often $200 to $500 out of pocket |
| Insurance | Covered by some plans with prior authorization | Usually not covered |
| Availability in 2025 | Widely available by prescription | Mostly discontinued, narrow exceptions remain |
Is Compound Tirzepatide as Effective as Zepbound?
No large head-to-head trial has compared Zepbound with compounded tirzepatide, so nobody can claim the two deliver identical results. The active molecule is the same, but potency, purity, and dose accuracy are not guaranteed in a compounded product.
Most people searching zepbound vs tirzepatide compound are really asking whether a pharmacy-mixed version can match the brand-name pen. Independent laboratory testing has found that some compounded samples contained more or less drug than the label stated, which can weaken results or increase side effects.
When someone asks whether compound tirzepatide is as effective as Zepbound, the accurate answer is that the evidence for compounded versions is thin. Brand-name tirzepatide has large randomized trials behind it, and compounded versions generally do not.
Cost, Insurance, and Access
Zepbound's list price is above $1,000 per month before insurance, though manufacturer self-pay vials and savings programs can cut that substantially for people paying cash. Coverage varies by plan, and prior authorization is common.
Compounded tirzepatide typically ran $200 to $500 per month and was rarely covered by insurance. That price gap drove most of the demand, but it came with trade-offs in oversight and consistency.
Many people also weigh tirzepatide vs ozempic cost, since semaglutide products are priced and reimbursed differently. For a wider look at how the two drug classes stack up, see semaglutide vs tirzepatide weight loss.
Safety and Sourcing
- Compounded drugs are not FDA-approved, even when they use an approved active ingredient.
- Drawing doses from a vial with a syringe increases the risk of measurement errors.
- Unverified online sellers may ship products with no sterility testing and no prescription.
- Common tirzepatide side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions.
- Serious risks include pancreatitis, gallbladder disease, and low blood sugar when combined with insulin or sulfonylureas.
If you are researching compounded tirzepatide vs tirzepatide products in general, the core distinction stays the same: one is approved and monitored, the other is not.
Researchers are also exploring newer candidates, and readers often ask about retatrutide vs tirzepatide: which is better and cagrilintide vs tirzepatide, though none of those drugs is FDA-approved for weight loss yet. Talk with a licensed healthcare professional before starting, stopping, or switching any weight-management medication.
How to Approach the Decision
Compounded tirzepatide is not a shortcut to the same product, and it is not something to swap in without medical guidance. A few practical steps help:
- Ask your prescriber whether an approved tirzepatide product is available and covered by your plan.
- Check manufacturer savings programs and self-pay pharmacy options before assuming the list price applies.
- Avoid any seller that ships tirzepatide without a prescription or refuses to name its pharmacy.
- Report side effects to your clinician and, for compounded products, to the FDA's MedWatch program.
Dose equivalence between compounded tirzepatide and Zepbound is usually assumed at the same milligram strength, but only a clinician should manage a switch. Never double up on doses while transitioning.
Frequently Asked Questions
Is compounded tirzepatide still available in the US?
Large-scale compounding of tirzepatide ended after the FDA resolved the shortage in late 2024 and the wind-down period closed in early 2025. A small number of state-licensed pharmacies may still compound under narrow, patient-specific exceptions. Availability varies by state, so ask your prescriber what is actually permitted where you live.
Is compounded tirzepatide the same as Zepbound?
They contain the same active ingredient, tirzepatide, but they are not the same product. Zepbound is FDA-approved and made under federal manufacturing standards, while compounded tirzepatide is not FDA-approved and its potency and purity are not guaranteed. Compounded versions also often include added vitamins such as B12 or B6.
Can I switch from compounded tirzepatide to Zepbound?
In most cases yes, with a prescriber's guidance. The right starting dose depends on your current dose, how long you have taken it, and any side effects you have had. Do not assume you can jump straight to a higher dose, because tirzepatide side effects are dose-dependent.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.